This paper reviews the abilities of positron emission tomography (PET) and single photon emission tomography (SPECT) to detect Parkinson’s disease, monitor its progression and the effect of therapy. It also provides insights on the role these two modalities provide in terms of discriminating atypical syndromes from Parkinson’s disease. Both PET and SPECT are sensitive means of detecting alterations in metabolism and blood flow in the brain and impairments in neurotransmitter function, especially dopaminergic, in the striatum and, more recently, in extrastriatal structures. To date, PET presents the added advantage of quantification, better sensitivity and resolution and a greater variety of tracers for both the dopaminergic and nondopaminergic systems.
Eidelberg D, Moeller JR, Ishikawa T, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson’s disease. Ann Neurol. 1996; 39:450-459.
4.
Garnett ES, Firnau G, Nahmias C.Dopamine visualized in the basal ganglia of living man. Nature. 1983; 305:137-138.
5.
Martin WRW, Palmer MR, Patlak CS, et al. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol. 1989; 26:535-542.
6.
Logan J.Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000; 27:661-670.
7.
Doudet DJ, Chan GLY, Holden JE, et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse. 1998; 29:225-232.
8.
Snow BJ, Tooyama I, McGeer EG, et al. Correlations in humans between premortem [18F]fluorodopa uptake, postmortem dopaminergic cell counts and striatal dopamine levels. Ann Neurol. 1993; 34:324-330.
9.
Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period in Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998; 64:314-319.
10.
Cumming P, Kuwabara H, Ase A, et al. Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem. 1995; 65:1381-1390.
11.
Lee C. S., Samii A., Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol. 2000; 47:493-503.
12.
Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol. 1990; 47:1290-1298.
13.
Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18Fdopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990; 28:547-555.
14.
Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease A 3D [18F] dopa-PET study. Brain. 1999; 122:1637-1658.
15.
Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995; 59:597-600.
16.
Kish SJ, Shannak K, Hornykiewicz O.Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med. 1988; 318:876-880.
17.
Ghaemi M, Rudolf J, Schmulling S, et al. FDG-and Dopa-PET in postencephalitic parkinsonism. J Neural Transm. 2000; 107:1289-1295.
18.
Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999; 45:577-582.
19.
Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson’s disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 1997; 2:222-229.
20.
Vingerhoets FJG, Snow BJ, Lee G, et al. Longitudinal fluorodopa positron emission tomography studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994; 36:759-764.
21.
Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain. 1996; 119:585-591.
22.
Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson’s disease. Ann Neurol. 1995; 38:379-388.
23.
Brooks DJ. PET studies and motor complications in Parkinson’s disease. Trends Neurosci. 2000; 10:S101-S108.
24.
Doudet DJ, Chan GLY, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab. 1999; 19:278-287.
25.
Jagust WJ, Eberling JL, Jordan S, et al. PET [18F]6-fluoro-L-m-tyrosine imaging of MPTP-lesioned primates. Society for Neuroscience abstracts1995;(Abstract).
26.
Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol. 1994; 36:237-239.
27.
Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: Implications for the symptomatic threshold. Neurology. 1997; 48:1578-1583.
28.
Frost JJ, Reich SG, Smith JS, et al. Positron emission tomographic imaging of the dopamine transporter with [11 C]-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol. 1993; 34:423-434.
29.
Nurmi E, Ruottinen HM, Kaasinen V, et al. Progression in Parkinson’s disease: A positron emission tomography study with a dopamine transporter ligand [18F] CFT. Ann Neurol. 2000; 47:804-808.
30.
Marek KL, Innis RB, Seybil JP. β-CIT/SPECT assessment of determinants of variability in progression in Parkinson’s disease. Neurology. 1999; 52 (Suppl. 2):A91(Abstract).
31.
Gordon I, Weizman R, Rehavi M.Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol.1996; 298:27-30.
32.
Vander Borght TM, Kilbourn MR, Desmond TJ, et al. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995; 294:577-583.
33.
Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996; 40:873-884.
34.
Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease: a PET study with [11C]raclopride. J Neurol Sci.1995; 132:156-161.
35.
Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration and progressive supranuclear palsy measured with 11C-raclopride and positron emission tomography. Ann Neurol.1992; 31:184-192.
36.
Pal PK, Wszolek ZK, Kishore A, et al. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinson Relat Disord. 2001; 7:81-88.
37.
Shinotoh H, Snow BJ, Chu NS, et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology. 1997; 48:1053-1056.
Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology. 1996; 46:1430-1436.
40.
de la Fuente-Fernandez R, Lu J, Sossi V, et al. Biochemical oscillations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence for increased dopamine turnover. Ann Neurol. 2001; 49:298-303.
41.
Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci. 1999; 12:1047-1140.
42.
Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Drug & Aging. 1996; 3:149-158.
43.
Cohen RM, Carson RE, Doudet DJ. Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Res. 1998; 802:292-296.
44.
Burn DJ, Rinne JO, Quinn NP, et al. Striatal opioid receptor binding in Parkinson’s disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome: a [11C]diprenorphin PET study. Brain. 1995; 118:951-958.
45.
Banati RB, Cagnin R, Myers R, et al. In vivo detection of activated microglia by[11C]PK11195-PET indicates involvement of the globus pallidus in idiopathic Parkinson’s disease. Parkinsonism & Related Disorders. 1999; 5:S56(Abstract).
